Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges including a significant reduction in shareholder value and management changes, alongside underperformance in multiple investment projects since its IPO in 2022 [1][2][4]. Group 1: Company Performance and Financials - He Eye Hospital's revenue is heavily concentrated in Liaoning Province, accounting for 94.31% of total revenue in 2024 [2]. - The company reported a net profit of 32.59 million yuan in 2022, a significant decline of 62.26% year-on-year, despite distributing dividends of 158 million yuan, which exceeded its net profit [2]. - For 2024, the company is projected to achieve a revenue of 1.096 billion yuan, reflecting a year-on-year decrease of 7.56%, with a net loss of 27.40 million yuan [3]. Group 2: Investment Projects and Challenges - Several investment projects initiated post-IPO have not met expected returns, with significant losses reported in projects such as the Beijing and Chongqing hospitals, which recorded losses of 90.85 million yuan and 69.51 million yuan respectively [4][5]. - The company has faced delays in project timelines, with the expected operational status for some projects pushed back to December 2026 and March 2027 [4][6]. Group 3: Management Changes and Shareholder Actions - In December 2025, the company underwent significant management changes, including the resignation of the general manager and the secretary of the board, which may impact operational stability [7][8]. - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, has announced plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total share capital, following a previous reduction in 2025 [8][9].

Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges due to management changes, underperformance of fundraising projects, and a significant decline in profits since its IPO in 2022 [1][2][3]. Group 1: Management Changes - In December 2025, the company experienced significant management changes, including the resignation of the general manager and the secretary of the board [8][9]. - The new general manager, He Xingru, is the son of the actual controllers, He Wei and He Xiangdong, indicating a continuation of family control [8][9]. Group 2: Financial Performance - He Eye Hospital's revenue for 2024 is projected to be 1.096 billion yuan, a decrease of 7.56% year-on-year, with a net loss of 27.3982 million yuan, a decline of 143.11% [2]. - The company reported a net profit of 54.3953 million yuan for the first three quarters of 2025, showing improvement compared to previous years, but the stock price continued to decline [8]. Group 3: Fundraising and Project Performance - The company raised approximately 1.296 billion yuan during its IPO, but many fundraising projects have not met expected returns or timelines [1][2]. - Specific projects, such as the Beijing and Chongqing new hospital projects, have incurred significant losses, with cumulative losses of 90.8468 million yuan and 69.5107 million yuan, respectively [3][6]. - The company has announced delays in project timelines, extending the expected operational status for several projects to 2026 and 2027 [5][6]. Group 4: Shareholder Actions - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total shares [9][10]. - Previous reductions by the same fund have already occurred, indicating a trend of shareholder exits amid declining stock performance [10][12].

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, primarily due to falling product prices despite an increase in sales volume for certain products [1][2]. Revenue and Profit Performance - In 2024, the company achieved an operating revenue of 238.87 billion yuan, a year-on-year decrease of 5.03%, and a net profit attributable to shareholders of 2.50 billion yuan, down 12.14% year-on-year [1]. - The decline in revenue was attributed to a drop in prices of key products like soybean and soybean oil, which outweighed the revenue contribution from increased sales volume [1]. Product Price Fluctuations - The gross margin for the company's two main businesses saw a slight increase, but the revenue from the feed raw materials and oil technology business, which accounts for about 40% of total revenue, decreased significantly by 10.37%, amounting to a reduction of 10.61 billion yuan [1][2]. - Despite a 10.32% increase in sales volume for feed raw materials, the profitability of the feed raw materials industry was squeezed due to weak domestic soybean prices and cautious purchasing by downstream feed and livestock enterprises [2]. Business Segment Analysis - The kitchen food business, which includes rice, flour, and oil, experienced a rise in sales volume but a slight decline in profit due to underperformance in retail channels and increased competition [2]. - The flour business faced losses in the first half of 2024 due to lower-than-expected market demand and fluctuating by-product prices, although the company expects improvement in the second half of the year [2]. Investment Projects and Future Strategy - The company has 81 production bases and is constructing new ones in strategic locations to reduce costs, but 10 investment projects have not met expected returns due to market demand and competition challenges [3]. - The company remains committed to its long-term development strategy in China, focusing on expanding its food and agricultural product businesses and reducing production, logistics, and marketing costs [3][4]. Innovation and R&D - The company is increasing its R&D investment, which grew by 2.41% to 274 million yuan, focusing on upgrading plant protein and grain product applications, as well as key technologies in condiments [4]. - Plans for 2025 include developing more functional and high-quality food products in response to consumer demand for healthier and diversified edible oils [4].